Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de bortezomib, lenalidomida y dexametasona (VRd) seguido de terapia CAR-T con BCMA en pacientes con leucemia primaria de células plasmáticas no elegibles para trasplante (CAREMM-002)

2 de noviembre de 2026 actualizado por: Institute of Hematology & Blood Diseases Hospital, China

Safety and Efficiency of VRd-based Regimen Combining BCMA CAR-T for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia. Patients received 3-4 courses of induction therapy with VRD-based regimen followed by infusion of BCMA CAR-T cells. Patients then received 2-3 courses of consolidation therapy, followed by maintenance therapy.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

20

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Gang An, PhD&MD
  • Número de teléfono: 86-022-23909171
  • Correo electrónico: angang@ihcams.ac.cn

Ubicaciones de estudio

      • Tianjin, Porcelana
        • Reclutamiento
        • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
        • Contacto:
          • Gang An, PhD&MD
          • Número de teléfono: 008613502181109
          • Correo electrónico: angang@ihcams.ac.cn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 18 years and ≤ 75 years.
  2. Participants with documented primary plasma cell leukemia according to IMWG diagnostic criteria (circulating plasma cells ≥5%, determined by morphology on peripheral blood smear; or absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L).
  3. Measurable disease, at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
  4. Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age (≥65); or Ineligible evaluated by researchers; or Eastern Cooperative Oncology Group Performance Status grade of 3 or 4; or Repeated hematopoietic stem cell mobilization failure; or Deferral of high-dose chemotherapy with ASCT as initial treatment.
  5. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
  6. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<2 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 30mL/min (calculated using Cockroft-Gault formula).
  7. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 70 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
  8. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
  9. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.

Exclusion Criteria:

  1. Documented active amyloidosis.
  2. Documented with central nervous system (CNS) invasion.
  3. Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
  4. Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
  5. Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and BCMA-CART cellular products.
  6. Seropositive for human immunodeficiency virus (HIV)
  7. Hepatitis B infection
  8. Hepatitis C infection
  9. Life expectancy of <6 months
  10. Women who are pregnant or breastfeeding
  11. Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication
  12. Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
  13. Received live attenuated vaccine within 4 weeks prior to study treatment.
  14. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
  15. Necessary medication or supportive therapy is contraindicated with study treatment.
  16. Any diseases or complications that may interfere with the study.
  17. Patients are not willing to or cannot comply with study scheme.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: VRD-based Regimen Combined With BCMA CART

VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.

BCMA CAR-T products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg.

Participants will receive VRD-based induction, BCMA CAR-T infusion, consolidation, and maintenance.

Patients receive a single intravenous infusion of one of two BCMA-directed autologous CAR T-cell products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg.

Bortezomib, Lenalidomide and Dexamethasone

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and Tolerability
Periodo de tiempo: Up to 2 year

The incidence of treatment-emergent adverse events (TEAEs)

Up to 2 year
MRD-negative rate
Periodo de tiempo: within 1 week after consolidation treatment

achieving MRD-negative, as determined by NGF after consolidation treatment

within 1 week after consolidation treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Complete response rate (CRR)
Periodo de tiempo: within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy

CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria

within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
Progression free survival (PFS)
Periodo de tiempo: Up to 2 year

Progression free survival is defined as the time from the date of enrollment to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first

Up to 2 year
Overall Survival (OS)
Periodo de tiempo: Up to 5 year

Overall survival is measured from the date of enrollment to the date of the participant's death.

Up to 5 year
Duration of Remission(DOR)
Periodo de tiempo: Up to 2 year

Duration of response is defined as the time from the first documented partial response (PR) or better to disease progression or death from any cause, whichever occurs first.

Up to 2 year

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
The duration of CART cell in vivo
Periodo de tiempo: Up to 1 year

The copies of BCMA-CART DNA in peripheral blood with qPCR method

Up to 1 year
Change from Baseline in Physical status assessed by International Myeloma Working Group Comprehensive Geriatric Assessment (IMWG-CGA) scores
Periodo de tiempo: Baseline up to 5 years

The IMWG-CGA was calculated by combining age, activities of daily living (ADL), instrumental ADL (IADL), and Charlson Comorbidity Index (CCI), which ranges from 0 to 5 with higher scores indicating worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by activities of daily living (ADL) scores
Periodo de tiempo: Baseline up to 5 years

The ADL includes 4 items (transfer, bed mobility, toileting, and eating), which range from 0 to 6 scores. A higher score represents worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by instrumental activities of daily living (IADL) scores
Periodo de tiempo: Baseline up to 5 years

The IADL includes 5 items (cooking, cleaning, transportation, laundry, and managing finances), which range from 0 to 8 scores. A higher score represents worse physical condition and greater weakness.

Baseline up to 5 years
Change from Baseline in Physical status assessed by Charlson Comorbidity Index (CCI)
Periodo de tiempo: Baseline up to 5 years

The CCI estimates the number and the severity of comorbidities, including nineteen diseases with a score varying from 1 to 6 for each of them in accordance to their severity. The score can range from 0 to 37. A higher score represents more severe comorbidities.

Baseline up to 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de agosto de 2023

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de julio de 2023

Primero enviado que cumplió con los criterios de control de calidad

29 de julio de 2023

Publicado por primera vez (Actual)

7 de agosto de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir